Salt Lake City, UT, United States
Salt Lake City, UT, United States

Juneau Biosciences is a biotechnology company based in Salt Lake City, Utah. The firm applies both population genetics and genomics approaches to identify the fundamental, molecular bases of major diseases that predominantly affect women. Founded in early 2007 by Dr. Kenneth Ward, the firm has focused so far on the development of molecular diagnostics and therapeutics for endometriosis. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Further Progress Toward Development of ARTGuide® Test SALT LAKE CITY, UT--(Marketwired - May 31, 2017) - Predictive Technology Group, Inc.'s ( : PRED) partner Juneau Biosciences, LLC presented four research studies at the 13th World Congress on Endometriosis in Vancouver, Canada. These presentations documented recent progress in developing a non-invasive test for endometriosis. In 2016, Predictive Therapeutics signed a license agreement with Juneau Biosciences, LLC for the commercialization of assays and related services for the prediction of endometriosis, and other health concerns, in the infertility market. This license extended the close relationship between the two companies. Given these developments, Predictive Therapeutics and Juneau Biosciences are now poised to launch their novel ARTGuide® test for women experiencing infertility. Commercial launch in the United States is now expected during H2 2017. Bradley Robinson, PRED CEO, states: "We look forward to the commercialization of the scientific developments that were presented at the World Congress on Endometriosis in Vancouver, Canada. The incorporation of these advancements into the ARTGuide® test has the potential to assist fertility specialists in designing the optimal course of care for couples struggling with fertility while transforming the global fertility market. ARTGuide® will provide "must-have" information for affected couples and their physicians." The ARTGuide® test is expected to change the way that advanced reproductive technologies ("ART") such as In Vitro Fertilization ("IVF") are used to help couples struggling to have a baby. Endometriosis affects more than 10 million women in the United States. Endometriosis occurs when the tissue similar to the lining of the uterus (womb) is found in other parts of the body, most commonly in the pelvis. Monthly bleeding and inflammation caused by these lesions may severely impact a woman's quality of life. Some affected women experience severe pain, others infertility, others problems with their periods, and some have no symptoms at all. Today, definitive diagnosis requires surgery. Due to the difficulties, invasiveness, and expense of diagnosing the condition, the majority of women with endometriosis suffer for over a decade before receiving treatment. Treatment may involve hormonal suppression or a targeted destruction of the abnormal tissue during surgery. Juneau Biosciences is a privately held medical genetics company conducting groundbreaking research to develop innovative diagnostic products for diseases that predominantly affect women. Launched in early 2007, the Salt Lake City, Utah-based firm has focused so far on the development of novel molecular diagnostics and therapeutics for endometriosis, a condition estimated to affect approximately 10% of reproductive-age females. This research is the basis of all the tests and therapies that we will produce, patent, and disseminate to signal the revolution in women's health care. Over the next several years, Juneau will launch additional programs for preterm labor and other gynecological and obstetric disorders. Juneau expects to improve the lives of millions of women through our genetic research and innovative health care solutions. Juneau Biosciences' knowledgeable team, state-of-the-art facilities, and innovative research techniques give us a unique advantage in developing diagnostics and treatments for women. Predictive Technology Group, Inc. (PRED), through its wholly owned subsidiaries, revolutionizes the treatment of serious and debilitating diseases through the commercialization of novel therapeutics leveraged by proprietary gene-based companion diagnostics. The Company develops and/or acquires proprietary technologies that open windows into the origin of human disease and the role that genes and their related proteins play in diseases' onsets and progressions. PRED's subsidiaries use gene-based information as cornerstones in the development of new diagnostics that assess a person's risk of disease and therapeutic products designed to effectively prevent and/or treat diseases. For further information about this release, contact Rich Kaiser, Investor Relations, YES INTERNATIONAL at 757-306-6090, yes@yesinternational.com, www.predictivetechnologygroup.com, www.predrx.com, www.predbiotech.com and www.yesinternational.com. To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking and are subject to risks and uncertainties, including the difficulty of predicting FDA approvals, acceptance and demand for new vaccines and other pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials, availability of additional intellectual property rights, availability of future financing sources, the regulatory environment and other risks the Company may identify from time to time in the future.


Endometriosis, defined by the presence of ectopic endometrial lesions, is a common disease in reproductive-age women that profoundly affects patients' quality of life. Various pathogenic models have been proposed, but the origin of endometriosis remains elusive. In this article, we propose that the mesothelial barrier, which protects the underlying stroma from endometrial transplants present in retrograde menstrual fluid, can be compromised by activation of the epithelial to mesenchymal transition (EMT) repair mechanism that lead to temporary loss of barrier integrity. Absent of the mesothelial barrier, endometrial cells can more readily adhere to the underlying peritoneal stroma and establish endometrial lesions. The hypothesis is based on the clinical and experimental observations that correlate the location of endometrial lesions with areas of mesothelial damage, together with genetic evidence that 4 genes associated with endometriosis are direct regulators of the actin-cytoskeleton, which coordinates mesothelial barrier integrity. It supports past observations that implicate the peritoneum in the pathogenesis of endometriosis and unifies previously disparate theories that endometriosis may be triggered by infection, mechanical damage, and inflammation since each of these mechanisms can induce EMT in the mesothelium. If the hypothesis is correct, inhibition of EMT in the mesothelial barrier provides a novel paradigm for the prevention and treatment of endometriosis. © Society for Gynecologic Investigation.


Albertsen H.M.,Juneau Biosciences | Chettier R.,Juneau Biosciences | Farrington P.,Juneau Biosciences | Ward K.,Juneau Biosciences
PLoS ONE | Year: 2013

Endometriosis is a common gynecological condition with complex etiology defined by the presence of endometrial glands and stroma outside the womb. Endometriosis is a common cause of both cyclic and chronic pelvic pain, reduced fertility, and reduced quality-of-life. Diagnosis and treatment of endometriosis is, on average, delayed by 7-10 years from the onset of symptoms. Absence of a timely and non-invasive diagnostic tool is presently the greatest barrier to the identification and treatment of endometriosis. Twin and family studies have documented an increased relative risk in families. To identify genetic factors that contribute to endometriosis we conducted a two-stage genome-wide association study (GWAS) of a European cohort including 2,019 surgically confirmed endometriosis cases and 14,471 controls. Three of the SNPs we identify associated at P<5×10-8 in our combined analysis belong to two loci: LINC00339-WNT4 on 1p36.12 (rs2235529; P = 8.65×10-9, OR = 1.29, CI = 1.18-1.40) and RND3-RBM43 on 2q23.3 (rs1519761; P = 4.70×10-8, OR = 1.20, Cl = 1.13-1.29, and rs6757804; P = 4.05×10-8, OR = 1.20, Cl = 1.13-1.29). Using an adjusted Bonferoni significance threshold of 4.51×10-7 we identify two additional loci in our meta-analysis that associate with endometriosis:, RNF144B-ID4 on 6p22.3 (rs6907340; P = 2.19×10-7, OR = 1.20, Cl = 1.12-1.28), and HNRNPA3P1-LOC100130539 on 10q11.21 (rs10508881; P = 4.08×10-7, OR = 1.19, Cl = 1.11-1.27). Consistent with previously suggested associations to WNT4 our study implicate a 150 kb region around WNT4 that also include LINC00339 and CDC42. A univariate analysis of documented infertility, age at menarche, and family history did not show allelic association with these SNP markers. Clinical data from patients in our study reveal an average delay in diagnosis of 8.4 years and confirm a strong correlation between endometriosis severity and infertility (n = 1182, P<0.001, OR = 2.18). This GWAS of endometriosis was conducted with high diagnostic certainty in cases, and with stringent handling of population substructure. Our findings broaden the understanding of the genetic factors that play a role in endometriosis. © 2013 Albertsen et al.


Patent
Juneau Biosciences | Date: 2013-03-07

The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.


Patent
Juneau Biosciences | Date: 2010-04-22

The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.


Patent
Juneau Biosciences | Date: 2016-09-05

The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.


Patent
Juneau Biosciences | Date: 2011-06-13

The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.


Patent
Juneau Biosciences | Date: 2012-09-04

The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.


Patent
Juneau Biosciences | Date: 2015-01-12

The present invention relates to novel genetic markers associated with endometriosis and risk of developing endometriosis, and methods and materials for determining whether a human subject has endometriosis or is at risk of developing endometriosis and the use of such risk information in selectively administering a treatment that at least partially prevents or compensates for an endometriosis related symptom.


Loading Juneau Biosciences collaborators
Loading Juneau Biosciences collaborators